Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative correction of coagulation factor XIII in brain tumor surgery
jRCTs051240079Recruiting
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of coagulation factor XIII in brain neoplasm and acquired factor XIII deficiency (2 arms). Primary endpoint: Change in coagulation factor XIII activity for 14 days after surgery. Started Sep 2025; status: recruiting.
02
Drugs
coagulation factor XIII
03
Conditions
brain neoplasmacquired factor XIII deficiency
Beyond the preview
Go deeper on jRCTs051240079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240079.